LQFM215 is a proline transporter (PROT) inhibitor. LQFM215 inhibits proline transport by competitively binding to the active site of PROT. LQFM215 effectively reduces hyperlocomotion and enhances social interaction.
LQFM215 (0.39-100 μM; 24 h ) shows low neurotoxicity against LUHMES cells[1].
LQFM215 (0.09-100 μM; 24 h ) shows concentration-dependent effects on growth of differentiated neural protrusions and cell survival in LUHMES cells[1].
LQFM215 (i.p.; 10-30 mg/kg; single dose) significantly reduces ketamine-induced hyperlocomotion in Swiss mice[1].